Editor-Last month the BMA warned that too few people in the United Kingdom know how to respond to a terrorist attack. 1 Its concerns about too few senior officials being aware of plans and recommendations to improve preparedness are sensible, but we believe that not enough medical staff are aware of their role in the event of a terrorist attack.
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Its concerns about too few senior officials being aware of plans and recommendations to improve preparedness are sensible, but we believe that not enough medical staff are aware of their role in the event of a terrorist attack.
We recently carried out a survey in the largest acute NHS trust of the south west of England to assess medical staff's knowledge about the local major incident plan. We sent questionnaires to the 107 doctors in North Bristol NHS Trust with a potential role in the mobile medical team if they were on duty during a major incident.
Seventy seven doctors replied (72%). Sixty nine were aware of the existence of the local major incident plan, but only 26 had read part or all of it. Only 11 of the responding doctors were aware of their potential role in the mobile medical team. Of these 11 doctors, only three thought themselves adequately trained for this position, and all three had been trained as medical incident officers.
Last year's National Audit Office report highlighted deficiencies in NHS plans to deal with major incidents in England. 2 It recommended upgrading training arrangements. Five months later some doctors are still unaware of their roles in the event of a terrorist attack. As a trust we are currently considering several measures to improve on our results. We suspect, however, that our findings are not unique and encourage other acute trusts to look closely at their staff's knowledge and training and act accordingly.
Contraindications to use of metformin

Age and creatinine clearance need to be taken into consideration
Editor-Jones et al criticise current guidelines highlighting possible contraindications to the use of metformin as too vague and potentially leading to underuse in patients with type 2 diabetes. 1 Although their desire for a "less ambiguous" approach seems sensible, their own guidelines still lack clarity.
They note that any specific value of serum creatinine concentration chosen as a cut-off point for prescribing metformin will be arbitrary because of variations in muscle mass and protein turnover. Despite this they then select-for undefined reasons-a serum creatinine value of 150 mol/l as the cut-off point in their guideline. They then say that caution should therefore be used in prescribing metformin for elderly patients. This is a vague statement, which could be interpreted as meaning that metformin should not be prescribed at all for elderly people, that specialist opinion should be sought or creatinine clearance calculated before it is prescribed, or that renal function or serum lactate concentration should be monitored after it is prescribed. 2 In addition, the authors do not define elderly.
Given that the growing majority of patients with type 2 diabetes are over 65 and that there is already evidence of undertreatment in such patients, 3 it seems particularly desirable to be as clear as is possible about this age group if the full benefits of treatment are to be attained.
Although the simple formulas that can be used to estimate creatinine clearance are not completely reliable, 4 it may be preferable for prescription to be related to such a calculated estimate of clearance, which takes into account a patient's age, rather than the serum creatinine value alone. 
Metformin may be useful in gestational diabetes
Editor-The editorial by Jones et al on contraindications to the use of metformin did not mention pregnancy. 1 Insulin is usually recommended in women with pregestational type 2 diabetes or gestational diabetes who require drug treatment. Given that pregnancy is a state of insulin resistance, metformin might be a logical alternative.
Cohort data support use of metformin in pregnancy. 2 In a report about women with polycystic ovary syndrome who conceived while taking metformin, continuation of treatment through pregnancy reduced the incidence of gestational diabetes. 3 One retrospective study has reported an increased rate of pre-eclampsia in pregnant women treated with metformin, but it is weakened by the lack of matched controls. 4 The perinatal losses reported in the metformin group cannot be attributed to metformin treatment.
We recently completed a pilot study in 30 women with gestational diabetes diagnosed by the criteria of the Australasian Diabetes in Pregnancy Society (ADIPS). The women were randomised to metformin or insulin treatment. They were matched for age, parity, body mass index, and gestation at entry (table). The study had ethics approval, and the women gave written informed consent.
The outcome measure of fetal cell activity, assessed by cord C-peptide concentration, was not different in the two groups (P=0.31; Mann-Whitney test; cord blood was stored from 17 women). Perinatal outcomes were not different (table), but numbers are too small to comment further. 5 A larger trial has been started (the metformin in gestational diabetes (MiG) study). It has adequate power to test the hypothesis that metformin treatment compared with insulin in gestational diabetes will have similar perinatal outcomes, improve insulin sensitivity in both mother and baby, and be associated with improved treatment acceptability. Ethics approval has been obtained, and recruitment has started. A follow up study of the offspring will invesLetters tigate potential effects of metformin in relation to later insulin sensitivity and subsequent health.
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Blanket banning of metformin two days before surgery may not be a good idea Editor-The editorial by Jones et al makes several recommendations about improving the prescription of metformin. 1 It is a pity that they advised stopping metformin two days before general anaesthesia when there is no evidence to suggest that this is warranted or even safe.
We conducted a Medline search using the keywords "metformin," "an(a)esthesia," "an(a)esthetics," "pre-operative," and "diabetes." We found no evidence supporting the unreferenced statement in their editorial.
Jones et al point out that tissue hypoxia is commonly the trigger for metformin associated lactic acidosis and that metformin has a short half life except in advanced renal failure. It follows that it is illogical to suspend metformin earlier than the evening before most surgery unless a degree of tissue hypoxia already exists.
Avoiding metformin in patients with established or expected tissue hypoxia, or when substantial impairment of hepatorenal function perioperatively may be anticipated, is perfectly sensible. May we suggest the recommendations reflect this? Emergency surgery, cardiac surgery, operations requiring deliberate hypotension, and major vascular surgery would be examples where this modified advice would apply.
Much elective surgery, however, does not fit this description, and the recommendation by Jones et al will, necessarily, only be applicable to patients undergoing elective surgery. A blanket recommendation to stop metformin two days before going to theatre is not necessary, safe, or practical.
Authors' reply
Editor-Our aim was to maximise the use of metformin in patients, in whom it would improve cardiovascular risk, using a pragmatic set of guidelines. Although the United Kingdom prospective diabetes study does not include patients aged over 65, 1 we did not intend to prohibit metformin use in this age group.
Metformin does not affect lactate concentrations or turnover in elderly patients 2 and, unlike insulin or sulphonylureas, does not cause hypoglycaemia, which can be problematic in older patients. Although, as we stated, a creatinine cut-off point of 150 mol/l is arbitrary, it is in keeping with guidelines from the Scottish Intercollegiate Group Network and the National Institute for Clinical Excellence for timing of referral for specialist opinion of type 2 diabetic patients with renal disease. 3 4 Any cut-off point based on a calculated creatinine clearance would be equally arbitrary.
Although there are good theoretical reasons why metformin may be useful in gestational diabetes and pregnant type 2 diabetic patients, its safety is yet to be established. The pilot data of Hague et al show an increase in caesarean births, neonatal hypoglycaemia, and need for special care nursery in the metformin group. It will be interesting to see if these trends persist in an adequately powered study.
We agree with Jones and Yates that evidence on the safety of metformin around the time of surgery is lacking. Their recommendations are helpful. Contrast media containing iodine rarely cause renal failure 5 -and, in a similar way, it may be overcautious to withdraw metformin after exposure to contrast media. None the less, prescribers could be open to criticism if they do not stop metformin treatment when there is even a risk of tissue hypoxia. illustrates the misleading policy signals that can emerge from an inadequate analytic method. 1 The paper finds little and inconsistent support for associations of prolonged waiting times with markers of capacity, independent sector activity, or need in the surgical specialties examined. Hard pressed policy makers might therefore infer that increased resources will not ameliorate the problem of NHS waiting times.
Increase in resources should lead to reduced waiting times
Yet an emerging economic literature, to which the authors do not refer, indicates the reverse. The key problem is that the waiting phenomenon may be the result of a subtle interaction between the demand for and supply of surgical capacity. Consequently, contemporary associations between capacity and waiting time will reflect a jumble of influences on demand and supply. A model is required that enables analysts to disentangle the effects of demand and supply.
Applying these principles to two years' data from the English hospital episode statistics database, we found that supply is indeed influenced by waiting times. 2 Our findings have since been replicated on a longer time series of data and for separate services.
3 They are also supported by a time series analysis of waiting list KH07 data. 4 The implication of this work is that a permanent increase in NHS resources will contribute to a reduction in waiting times, other things being equal.
Martin et al outline some of the limitations of their study, and we, too, acknowledge that our work has its own shortcomings. However, simple cross sectional associations between waiting time and various other factors are far too flimsy a basis from which to make policy inferences, particularly when there is clear evidence that the waiting phenomenon reflects both the pressures of demand and supply. 
New structures of governance are needed
Editor-Klein sees the "cacophony of accountabilities" for new NHS foundation hospitals as a weakness, 1 but I would argue that it may be their greatest strength.
For half a century, the NHS has been organised as an administrative bureaucracy led from Whitehall, and the many structural reforms of the past two decades have done nothing to change this. No other major public service is so centralised. This bureaucracy has struggled in recent years to absorb increased resources and to deliver improved performance, and the difficulties of running this £70bn organisation by administrative diktat from Richmond House have become painfully apparent.
Foundation hospitals offer a vision of a new model of governance and accountability in the NHS, replacing a vertical hierarchy topped by the Department of Health with a network of more autonomous healthcare providers still working within the values, standards, and requirements of the NHS. 2 Foundation hospitals will have a network of accountability relations with their local communities, local government, other NHS organisations, national regulators, and the Department of Health. Plurality will replace the department's current, unhealthy monopoly of control.
Although the government's guidance on the practical details of foundation hospitals still needs work, 3 the principle seems to have been accepted across the political spectrum. It does not make political, financial, or organisational sense to try to run the NHS from the Department of Health in Whitehall, and new structures of governance are needed that will make NHS organisations more accountable to the communities they serve. 
Kieran M J Walshe director of research management
Drug treatment of hypertension
Conclusion of editorial is somewhat flawed
Editor-In his analysis of the major results of the recently published antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT), Williams concludes that the key message from this trial is that what matters most is getting blood pressure controlled and that this is overwhelmingly more important than the means. 1 2 ALLHAT showed that all blood pressure drugs were not "created" equally. 2 Williams correctly points out important differences in the secondary cause specific end points between chlorthalidone and its active comparators: doxazosin (increased congestive heart failure), lisinopril (increased stroke and coronary end points), and amlodipine (increased stroke). For this very reason, the data safety monitoring board of the ALL-HAT trial recommended discontinuance of the doxazosin arm.
There are other characteristics of blood pressure drugs, other than their effect on so called hard end points, that are as important as getting blood pressure controlled. These include cost, profile of adverse effects, ease of use (once daily versus several daily doses), and interactions with other drug agents. In all aspects, thiazide type diuretics come up tops as first line agents. This was amply shown in the systolic hypertension in the elderly programme (SHEP) and Medical Research Council studies, in which thiazide diuretics were associated with a greater than 40% reduction in the risk of stroke in patients with isolated systolic hypertension; these studies were conducted and completed more than a decade ago. 3 4 ALLHAT also showed the differences in tolerability between agents, and the particular difficulty in controlling blood pressure to target values especially with angiotensin converting enzyme inhibitors in black patients.
In choosing a therapeutic agent to lower blood pressure and reduce cardiovascular risk, one must look at not only the blood pressure lowering effect but also important clinical end points that we are aiming to prevent, as well as issues such as cost and tolerability. 
Daniel G Hackam chief medical resident
Thiazides with your pension?
Editor-As Williams says in his editorial, the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALL-HAT) reaffirms the use of thiazide diuretics as a first line treatment for the older population with hypertension. 1 But what about older patients who are not hypertensive?
For more than 20 years we have seen numerous studies that indicate that thiazide diuretics, in the usual antihypertensive doses, preserve bone mineralisation, 2 and, importantly, the use of thiazide diuretics seems to be associated with a 30-40% reduction in the risk of hip fracture. 3 4 However, if we are to start our thiazide at the same time we pick up our pension then we really need a randomised controlled trial. It is perverse that we do not have such a study because thiazides are so cheap. If modern health care is to maximise its potential, then healthcare agencies need to be prepared to pick up the costs for appropriate research and relicensing of older drugs, and not just the costs of the
Identifying malnourished children may not be easy
Editor-Bahn et al propose to use the World Health Organization's criteria for diagnosing malnutrition, 1 which include calculating Z scores for weight for height, and height for age.
Rural hospitals in resource poor areas are often severely understaffed but at the same time have high admission rates of especially small children. The amount of strain that measuring the heights of all admitted children puts on the medical and nursing staff should not be underestimated. Measuring is considered to be too time consuming and of little value in establishing the diagnosis and is therefore often left out in the assessment of the child.
In many hospitals in rural Kenya malnutrition is diagnosed only on clinical grounds such as weight, presence of pedal oedema, and discolouration of the hair. To try to measure the correlation between clinical diagnosis and more objective assessment through anthropometric indices, we conducted a study in Misikhu Mission Hospital in western Kenya. 2 For five months all admitted children under the age of 5 years (n=1130), had their anthropometric indices calculated by using Epi-Info software and then compared with the clinical diagnosis.
Sixteen per cent of the admitted children were wasted (weight for height score < 2SD below the mean), and an additional 16% were stunted (height for age score < 2SD below the mean). Just 14% of the wasted children and 11% of the stunted children were identified by clinical assessment as having malnutrition and would have got appropriate treatment when only clinical variables were taken into account at the time of diagnosis.
Measuring height cannot be left out when assessing the possible presence of malnutrition in a child. Once the diagnosis is made, the guidelines mentioned by Bahn et al should help the doctor in the actual treatment of malnourished children. 
Frank van Leth clinical epidemiologist
Skin scarring: new insights may make adjustment easier
Editor-Skin scarring is a clinical problem that can cause many psychological and social difficulties-some as a result of the cause of the scarring (for example, trauma), some related to the effects (for example, itching), and many to the appearance of the scar itself. In the review by Bayat et al their argument that a decision to treat will depend on site, symptoms, severity of functional impairment, and stigma would be enhanced by the inclusion of two crucial insights from recent psychological literature, insights that can make it much easier for patients to adjust to these problems. 1 Firstly, much research has now confirmed that the seriousness of psychosocial sequelae is not positively correlated with the severity, size, or location of scarring. 2 It is therefore important in the clinical examination and assessment process that doctors do not make assumptions about the psychosocial impact of scarring-it is important to ask patients about how self conscious they feel, for example, and how noticeable they feel the scar is to others because these factors are likely to be more predictive of distress. 3 Secondly, recognising that even with the skills of surgeons and others, scars cannot yet be made to disappear has prompted new psychosocial interventions to be developed for patients distressed by disfigurements of any kind, including scarring, to their face, hands, and body. These have focused on the strengthening of self esteem and communication skills (so as to manage the reactions of other people) and are available in various formats including in self-help guides produced by a charity, Changing Editor-According to Delamothe, a consensus is emerging on how the internet will change the economics of scientific publishing. 1 As far as I am aware no journal relying solely on charging authors for online publication has yet managed to derive sufficient revenue from this model to meet its running costs.
Our approach at Oxford University Press is to maximise the dissemination of our online journals by adapting the traditional subscription model to extend online access to groups of institutions, companies, whole states, or countries. We also offer free online access to the poorest developing countries, and we participate in archives such as those provided by PubMed Central and HighWire Press. In addition, we are experimenting with other pricing models, including charging authors for publication and providing "free" online versions subsidised from print revenues or by advertising.
I think that, although the virtual world is changing the economics of scientific publishing, in the real world no single model is likely to meet the needs of every author or reader. Open access journals funded by author charges may eventually prove to be the economic model of choice in some cases, but most journals, unless they also benefit from grants or subsidies, will need to rely on a mixture of economic models to continue to support the costs of online publication.
Cautious welcome is in order
Editor-I welcome the development outlined by Delamothe that authors should pay for publication of their work, while appreciating the difficulties many journals face in providing free access, as well as the authors' desire to publish and retain copyright of their work. I wish foundations and scientists (peer reviewing and writing for journals) supported groups of scientists taking publishing into their own hands by using the web, rather than supporting megalomaniac organisations that aim to centralise and dominate. Open access has been made possible through the internet, and the internet is a wonderful decentralised medium. Let's keep it that way. We are just trying to free ourselves from the oligarchy of large publishing houses. Why do we need to create a new mega-organisation that tries to monopolise publishing? Establishing an online journal, setting up a peer review system, and getting the journal indexed in bibliographic databases is not rocket science. The group of editors that runs JMIR has decided that it needs neither BioMed Central nor PLoS for that.
PLoS should stay what it was-an advocacy group-but not enter into a competition with existing open access journals. If PLoS wants to use the $9m wisely, it should use it to support existing open access journals rather than competing with them.
